Print Friendly, PDF & Email

NCT/Study#

NA /

PTX-001-004

A Phase 2 Study Of The Safety and Tolerability of Sargramostim Added To Standard Of Care Ipilimumab Containing Checkpoint Inhibitor Therapy In Patients With Solid Tumors

DISEASE GROUP:
Solid Tumors
current phase:
II
STUDY STATUS:
Active
Location:
For More information: